IP Library Granted Patent US 10,842,751
Granted Patent B2
US 10,842,751 · App. 16/791,398 · Granted Nov 24, 2020

Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,842,751
App. No.
16/791,398
Granted
Nov 24, 2020
Kind
B2
Abstract

The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.

Claims (11)

1. A tablet comprising a first layer comprising an amorphous dispersion formulation of doravirine, and a second layer comprising lamivudine and tenofovir disoproxil fumarate.

2. The tablet of claim 1 wherein the first layer further comprises a polymer.

3. The tablet of claim 2 wherein the polymer is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, polyvinylpyrrolidinone and polyvinylpyrrolidinone-polyvinylacetate copolymers.

4. The tablet of claim 3 wherein the polymer is hydroxypropyl methyl cellulose acetate succinate.

5. The tablet of claim 1 wherein the first layer further comprises microcrystalline cellulose.

6. The tablet of claim 1 wherein the first layer further comprises croscarmellose sodium.

7. The tablet of claim 1 wherein the second layer further comprises microcrystalline cellulose.

8. The tablet of claim 1 further comprising a film coat.

9. The tablet of claim 1 comprising 50 mg of doravirine, 150 mg of lamivudine and 150 mg of tenofovir disoproxil fumarate.

10. The tablet of claim 1 comprising 100 mg of doravirine, 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate.

11. A tablet comprising (i) a first layer comprising an amorphous dispersion formulation of doravirine, hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, and croscarmellose sodium, and (ii) a second layer comprising lamivudine, tenofovir disoproxil fumarate and microcrystalline cellulose.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: PANMAI, SANTIPHARP; TATAVARTI, ADITYA; FARRINGTON, ANDREW M.; BIYYALA, VARSHA; ALLAIN, LEONARDO R.; NEFLIU, MARCELA; KLINZING, GERARD R.; REN, JIE; LAMM, MATTHEW
To: MERCK SHARP & DOHME CORP.
Reel/Frame 051824/0105 →